List view / Grid view
26 May 2015 | By Victoria White
Faron has entered into strategic agreements with CMS and A&B Ltd for the development and commercialisation of Traumakine for the treatment of ARDS...
26 May 2015 | By Victoria White
CHMP has adopted a positive opinion of Simponi for the treatment of adults with severe active non-radiographic axial spondyloarthritis...
26 May 2015 | By Victoria White
Amgen has announced the termination of its co-development and commercialisation agreement with AstraZeneca for brodalumab...
22 May 2015 | By Victoria White
The CHMP has adopted a positive opinion for the marketing authorisation of Amgen’s Repatha for use in certain patients with high cholesterol...
22 May 2015 | By Victoria White
Cristal Therapeutics has appointed Rob Liskamp, Twan Lammers, Alberto Gabizon, Maninder Hora and William Zamboni to its new Scientific Advisory Board...
22 May 2015 | By Victoria White
The CHMP has adopted a positive opinion recommending that nivolumab be granted approval for the treatment of NSCLC after prior chemotherapy in adults...
22 May 2015 | By Victoria White
Tris Pharma has announced that the FDA has accepted for review its New Drug Application for Dyanavel XR, an Extended-Release Oral Suspension...
22 May 2015 | By Victoria White
The Phase III study of everolimus in patients with advanced nonfunctional neuroendocrine tumours (NET) of GI or lung origin met its primary endpoint...
22 May 2015 | By Victoria White
The US Food and Drug Administration (FDA) has granted Fast Track designation to ReNeuron’s human Retinal Progenitor Cell (hRPC) therapy candidate for retinitis pigmentosa.
22 May 2015 | By Victoria White
Novartis has announced positive results from two pivotal Phase III clinical trial programmes for QVA149 and NVA237 in patients with moderate-to-severe COPD...
22 May 2015 | By Victoria White
Nabriva has announced the appointment of Elyse Seltzer, MD, as Chief Medical Officer. Dr Seltzer assumes the role from Dr William Prince...
21 May 2015 | By Victoria White
Data presented from the Clostridium difficile Infection (CDI) Service Evaluation study shows that the adoption pattern of treatment impacts CDI outcomes...
21 May 2015 | By Victoria White
The FDA has granted Orphan Drug Designation to Alnylam’s revusiran for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis)...
21 May 2015 | By CBR International
CBR International’s Scientific Experts Supporting Mapp Biopharmaceutical Pertaining to ZMAPPTM...
21 May 2015 | By Victoria White
Phase 3 study of sarilumab met its co-primary efficacy endpoints of a greater improvement in signs and symptoms of rheumatoid arthritis...
